Know Cancer

forgot password

Molecular Fingerprinting of Lung Cancer

18 Years
Open (Enrolling)
Lung Cancer

Thank you

Trial Information

Molecular Fingerprinting of Lung Cancer


- Develop statistical and computational methods for modeling the relationships between
multiple variable protein and RNA expression data and clinical endpoints using both
supervised and unsupervised classification and pattern recognition approaches.

- Determine protein and RNA expression fingerprints on completely resected non-small cell
lung cancer without prior chemotherapy.

- Correlate protein and RNA expression fingerprints with T-stage and nodal involvement at
the time of surgery, and collect outcome data to allow correlation with recurrence
(local and/or distant) and survival.

OUTLINE: This is a multicenter study.

Any excess tissues removed from surgery and would otherwise be discarded (tissues not used
for diagnosis and/or treatment decision making) are obtained for this study. Tissue are
analyzed for molecular features that predict biologic behavior. Quantitation of RNA, gene
expression profiles, and protein expression patterns are assessed by matrix-assisted laser
desorption/ionization time of flight mass spectroscopy and microarray analysis.

Medical records are reviewed to obtain information about results of tests associated with
cancer diagnosis. Further progress in cancer treatment and tumor behavior after surgery are
followed via record review.

Inclusion Criteria

Inclusion criteria

- Diagnosis of non-small cell lung cancer

- Clinical stage I and II disease

- Resectable disease and complete surgical resection planned

- Treated on companion studies at Vanderbilt University, the Veterans Administration
hospital, St. Thomas, and Vanderbilt-Ingram Cancer Center Affiliate Network

- Tumor specimen samples must be available at resection

Exclusion criteria

- Chemotherapy before surgery

- Radiotherapy before surgery

Type of Study:


Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

Protein and RNA expression fingerprints from collected samples

Outcome Time Frame:

after collection of designated samples

Safety Issue:


Principal Investigator

Pierre P. Massion, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Vanderbilt-Ingram Cancer Center


Unites States: Vanderbilt University Human Research Protection Program

Study ID:




Start Date:

May 2001

Completion Date:

July 2015

Related Keywords:

  • Lung Cancer
  • stage I non-small cell lung cancer
  • stage II non-small cell lung cancer
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms



Vanderbilt-Ingram Cancer Center Nashville, Tennessee  37232-6838
Veterans Affairs Medical Center - Nashville Nashville, Tennessee  37212
Vanderbilt-Ingram Cancer Center - Cool Springs Nashville, Tennessee  37064
Vanderbilt-Ingram Cancer Center at Franklin Nashville, Tennessee  37064
Dan Rudy Cancer Center at Saint Thomas Hospital Nashville, Tennessee  37205